FDAnews Drug Daily Bulletin

Vanda Pharmaceuticals Acquires Rights to NK-1 Receptor Antagonist From Eli Lilly

April 17, 2012
A A
Vanda Pharmaceuticals announced that it has acquired an exclusive world-wide license from Eli Lilly to develop and commercialize a small molecule neurokinin 1 receptor (NK-1R) antagonist for all human indications.
Genetic Engineering & Biotechnology News